CIP
RLMD icon

Chartwell Investment Partners’s Relmada Therapeutics RLMD Stock Holding History

Chartwell Investment Partners’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-7,328
Closed -$276K – 443
2020
Q3 		$276K Hold
7,328
– – 0.01% 410
2020
Q2 		$328K Sell
7,328
-2,154
-23% -$91.1K 0.01% 394
2020
Q1 		$323K Buy
9,482
+702
+8% +$28.3K 0.02% 380
2019
Q4 		$342K Buy
+8,780
New +$267K 0.01% 395

Other funds holding RLMD

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Chartwell Investment Partners's RLMD Position: Q4 2020 in Review

Chartwell Investment Partners sold out of Relmada Therapeutics (RLMD) in Q4 2020, closing a stake of 7,328 shares — an estimated $276K sold.

Chartwell Investment Partners first reported a position in RLMD in Q4 2019 and held it in 4 quarters. The position peaked at $342K in Q4 2019. 80 funds tracked by Wall St. Rank hold RLMD as of Q4 2020.

  • Chartwell Investment Partners reported no remaining Relmada Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Chartwell Investment Partners sold 7,328 Relmada Therapeutics shares in Q4 2020, an estimated $276K.
  • Chartwell Investment Partners first reported a position in Relmada Therapeutics in Q4 2019 and held it in 4 quarters.
  • Chartwell Investment Partners's Relmada Therapeutics position peaked at $342K in Q4 2019.
  • 80 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2020.

Based on Chartwell Investment Partners's 13F filing for Q4 2020, filed 9 Feb 2021.